These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17611619)

  • 1. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
    Adhikary D; Behrends U; Boerschmann H; Pfünder A; Burdach S; Moosmann A; Witter K; Bornkamm GW; Mautner J
    PLoS One; 2007 Jul; 2(7):e583. PubMed ID: 17611619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
    Ning RJ; Xu XQ; Chan KH; Chiang AK
    Immunology; 2011 Oct; 134(2):161-71. PubMed ID: 21896011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders.
    Linnerbauer S; Behrends U; Adhikary D; Witter K; Bornkamm GW; Mautner J
    PLoS Pathog; 2014 May; 10(5):e1004068. PubMed ID: 24853673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
    Mautner J; Bornkamm GW
    Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
    Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-uniform
    Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
    Front Immunol; 2019; 10():2489. PubMed ID: 31736946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
    Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
    Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential targeting and shifts in the immunodominance of Epstein-Barr virus--specific CD8 and CD4 T cell responses during acute and persistent infection.
    Woodberry T; Suscovich TJ; Henry LM; Davis JK; Frahm N; Walker BD; Scadden DT; Wang F; Brander C
    J Infect Dis; 2005 Nov; 192(9):1513-24. PubMed ID: 16206065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
    Croft NP; Shannon-Lowe C; Bell AI; Horst D; Kremmer E; Ressing ME; Wiertz EJ; Middeldorp JM; Rowe M; Rickinson AB; Hislop AD
    PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles.
    Adhikary D; Behrends U; Feederle R; Delecluse HJ; Mautner J
    J Virol; 2008 Apr; 82(8):3903-11. PubMed ID: 18272580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
    Quinn LL; Zuo J; Abbott RJ; Shannon-Lowe C; Tierney RJ; Hislop AD; Rowe M
    PLoS Pathog; 2014 Aug; 10(8):e1004322. PubMed ID: 25144360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunodominant CD8 T cell response to Epstein-Barr virus.
    Houssaint E; Saulquin X; Scotet E; Bonneville M
    Biomed Pharmacother; 2001 Sep; 55(7):373-80. PubMed ID: 11669500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
    Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
    Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human T cell immune response to Epstein-Barr virus.
    Landais E; Saulquin X; Houssaint E
    Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
    Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
    J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
    Sebelin-Wulf K; Nguyen TD; Oertel S; Papp-Vary M; Trappe RU; Schulzki A; Pezzutto A; Riess H; Subklewe M
    Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1.
    Landais E; Saulquin X; Scotet E; Trautmann L; Peyrat MA; Yates JL; Kwok WW; Bonneville M; Houssaint E
    Blood; 2004 Feb; 103(4):1408-16. PubMed ID: 14563644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic CD4+ T-cells specific for EBV capsid antigen BORF1 are maintained in long-term latently infected healthy donors.
    Dowell AC; Haigh TA; Ryan GB; Turner JE; Long HM; Taylor GS
    PLoS Pathog; 2021 Dec; 17(12):e1010137. PubMed ID: 34882759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.